The Post-operative Pain Management Market report offers immense growth opportunities across developing as well as developed economies. The research report intends to provide factors influencing the Post-operative Pain Management Market and gain all possible information with respect to market. The analysis of reports gives a satisfactory result to the user.

Pune, India -- (SBWire) -- 10/26/2018 --The Global Post-operative Pain Management Market has been segmented on the basis of pain type, product, application and target area. Based on pain type, the post-operative pain management market is segmented into acute pain, moderate pain and severe pain. Based on product, the post-operative pain management market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), antiepileptic drugs, COX-2 inhibitors, opioids and other analgesics.

Based on application, the post-operative pain management market is segmented into cancer pain, arthritic pain, neuropathic pain, musculoskeletal pain, migraine and others. Based on target area, the post-operative pain management market is segmented into back, legs, hand and arms and others.

To Get Sample PDF Copy of Report visit https://www.marketresearchfuture.com/sample_request/1246

Post-operative Pain Management Market - Outlook

The Post-operative Pain Management Market report proffers a deep landscape and upcoming expectations of the Post-operative Pain Management Industry. The Post-operative Pain Management Market report supplies pivotal information about the market, including suggestions from Industry experts, and the current advancements and evolution of the Post-operative Pain Management industry.

Increasing number of surgeries and rising demand for the pain management treatment is the major reason for the growth of the market. Analgesics are habit forming drugs and can also damage the renal system, this is the major restraining factor for the market.

According to cancer research UK, in 2012, globally over 14.1 million of new cancer cases were registered. The treatment for the all types of cancer are nearly similar, thus increasing prevalence of cancer has boosted the development of the new treatments.

According to Migraine Research Foundation, (2014), migraine was the 3rd most prevalent illness in the world. Nearly 1 in 4 U.S. households includes someone with migraine. Moreover, 12% of the population including children have migraine problem. 18% of American women, 6% of men, and 10% of children experience migraines. Mostly migraine occurs at the age of 25-55.

Global Post-operative pain management market was expected to grow at a CAGR of 5.4% during forecasted period 2017-2023.

Key Players for Global Post-operative Pain Management Market

Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly Company (U.S), Pfizer (U.S), Johnson & Johnson (U.S), Purdue Pharma (U.S), Endo Pharmaceuticals Plc. (U.S), Forest Laboratories Inc. (U.S), GlaxoSmithKline Plc. (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter International Inc. (US), Valeant Pharmaceuticals International Inc. (Canada) are some of the prominent players at the forefront of competition in the Global Post-operative Pain Management Market and are profiled in MRFR Analysis.

Global Post-operative Pain Management Market - Competitive Analysis

Many of the top companies are launching new and novel drug treatment to increase their market. Because of side effect and habit forming property of the therapy major players are concentrating on development of better analgesic. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.

Teva Pharmaceutical Industries Ltd. is the Israeli multinational pharmaceutical company working in the development and manufacturing of the drugs. Celecoxib intravenous is the major products of the company. Company has signed a collaborative agreement with Regeneron for the development of fasinumab which is a pain management drug. In first quarter of 2017 company has accounted a revenue of $ 5.6 billion. In 2014, company has acquired Labrys Biologics. This acquisition will help to achieve its goal of becoming a global leader in pain drugs by 2020.

Novartis, one of the leading pharmaceutical companies headquartered in Switzerland. In Nov 2016, company has plan a phase II trial for the NCT02961062 in the treatment of postoperative pain. They have almost completed the trials for the SAF312 in postoperative dental pain patients and company is expecting to launch the product soon. In May 2017, Novartis has sign a deal of $ 293 million with Durect for pain killer Posimir.

To Browse Complete Report visit https://www.marketresearchfuture.com/reports/post-operative-pain-management-market-1246

Pfizer Inc. a world's largest American pharmaceutical companies headquartered in US. Parecoxib is the widely used drug of this company. Due to Lyrica which is a pain treatment the net income of the company has increased by 13 % in 2016. Company has completed the clinical trials for the EMBEDA for the post-operative pain management.

Forest Laboratories which is the American Pharmaceutical company headquartered in US. Forest Laboratories and Trevena Inc. has announce Collaboration for development of TRV027 which is used in the post-operative pain treatment.

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.